Sort   by:  
 Page size 
UnknownSafety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.
Not available
S-EPMC4033489 | biostudies-literature
UnknownPharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Not available
S-EPMC4278557 | biostudies-literature
UnknownIntegrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Not available
S-EPMC4622749 | biostudies-literature
UnknownProposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Not available
S-EPMC6256001 | biostudies-literature
UnknownA large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Not available
S-EPMC7256126 | biostudies-literature
UnknownThe effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Not available
S-EPMC4823635 | biostudies-literature
Sort   by:  
 Page size